Drug reaction with eosinophilia and systemic symptoms associated with raltegravir use: Case report and review of the literature

摘要

Raltegravir (RAL) is the first integrase strand transfer inhibitor against HIV [1] and it is placed within first-line options in the treatment of HIV infection [2]. It is also the first agent of a new class of antivirals, which now includes two additional drugs [2], namely elvitegravir and dolutegravir.